About this Research Topic
Flow cytometry has now become an indispensable tool in clinical diagnostics, immunophenotyping, experimental medicine, understanding disease pathogenesis and in many more applications. With the increase in the applicability and versatility of flow-cytometry based techniques, the complexity of flow cytometric data is also increasing. Therefore, it has become clear that flow cytometric experimental protocols, data analysis and interpretation need to be held to high standards, particularly if they are to be used widely in clinical diagnostic applications and if novel applications of flow cytometry are to find global acceptability. At the same time, innovations in flow cytometry applications must continue.
The goal of this research topic is to invite articles that demonstrate innovative and rigorous applications of flow cytometry in either clinical diagnostics or, disease pathogenesis (experimental medicine). The editors hope to highlight diverse and novel utilization of flow cytometry across the health sciences and more importantly, they wish to highlight the correct way to carry out flow cytometry experiments. This research topic will emphasize the correct experimental methodology and reporting of flow cytometric data in all submissions.
Authors are encouraged to submit original research, reviews and mini reviews. The thematic areas will include, but are not limited to- Prime flow RNA assay, cytokine detection, phospho-flow, cell health, stress and cytotoxicity assays, cell division and proliferation assay, intracellular calcium flux assay, small particle flow cytometry, multicolor immunophenotyping, transfection efficiency and membrane potential assays. Please note, any paper submitted to this research topic must have a very detailed study protocol described in the methods. Maximum possible adherence to MiFlowCyt guidelines is recommended.
We look forward to receiving your work.
Declaration of Conflict of Interest: Topic Editor Dr. Hemant Agrawal is the founder and CEO of Flowcytometry Solutions Pvt Ltd. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
The goal of this research topic is to invite articles that demonstrate innovative and rigorous applications of flow cytometry in either clinical diagnostics or, disease pathogenesis (experimental medicine). The editors hope to highlight diverse and novel utilization of flow cytometry across the health sciences and more importantly, they wish to highlight the correct way to carry out flow cytometry experiments. This research topic will emphasize the correct experimental methodology and reporting of flow cytometric data in all submissions.
Authors are encouraged to submit original research, reviews and mini reviews. The thematic areas will include, but are not limited to- Prime flow RNA assay, cytokine detection, phospho-flow, cell health, stress and cytotoxicity assays, cell division and proliferation assay, intracellular calcium flux assay, small particle flow cytometry, multicolor immunophenotyping, transfection efficiency and membrane potential assays. Please note, any paper submitted to this research topic must have a very detailed study protocol described in the methods. Maximum possible adherence to MiFlowCyt guidelines is recommended.
We look forward to receiving your work.
Declaration of Conflict of Interest: Topic Editor Dr. Hemant Agrawal is the founder and CEO of Flowcytometry Solutions Pvt Ltd. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: Flow cytometry, FACS, Diagnostics, Immunophenotyping, RNA assay, Signaling, phospho-flow, Flow assisted cell sorting, Pathogenesis, Multi-color flow cytometry, Small particle flow cytometry
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
